Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 454
1.
JNMA J Nepal Med Assoc ; 62(270): 148-151, 2024 Feb 24.
Article En | MEDLINE | ID: mdl-38409977

Orbital tuberculosis is a rare form of extrapulmonary tuberculosis involving orbital soft tissue, periosteum, bones and lacrimal glands. This is a case report of a 6-year-old male child who presented with swelling of the right upper eyelid. He had normal visual acuity without signs of diplopia or ophthalmoplegia. The tuberculin skin test was reactive and the computed tomography scan showed peripherally enhancing collection with bony erosion and intracranial extension in the extraconal space of the superolateral right orbit. Orbital exploration was done which showed caseous material. The histological examination revealed necrotizing granulomatous tissue. The caseous material on Ziehl Neelsen staining confirmed acid-fast bacilli causing a tubercular abscess. The child is currently on anti-tubercular therapy planned for 12 months. Orbital tuberculosis might or might not be in association with pulmonary tuberculosis and should always be taken into consideration while dealing with chronic inflammatory orbital disease and an orbital mass. Keywords: case reports; orbit; tuberculosis.


Orbital Diseases , Tuberculosis, Ocular , Tuberculosis , Male , Child , Humans , Abscess/diagnostic imaging , Abscess/complications , Tuberculosis/complications , Tuberculosis, Ocular/complications , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Orbital Diseases/diagnosis , Tomography, X-Ray Computed
2.
Eur J Ophthalmol ; 34(1): NP41-NP43, 2024 Jan.
Article En | MEDLINE | ID: mdl-37345304

INTRODUCTION: Tuberculosis can involve any organ in the body including ocular tissue of which the uveal tissue is most commonly infected. Choroidal involvement ranges from choroidal tubercles to granulomas. This is one of the few cases of a solitary choroidal granuloma with no other systemic symptoms in an immunocompetent child. METHOD: A case report. RESULTS: A 12-year-old female, presented with diminution of vision in the left eye for a month. The anterior segment of her left eye was normal. A fundus examination revealed an isolated orangish-yellow choroidal mass, 4 DD in size, involving the posterior pole with overlying subretinal exudation. CT scan of the thorax showed large pulmonary, cervical and pancreatic lymph nodes, along with lytic lesions of the thoracic vertebrae. Excision biopsy of the cervical lymph nodes showed caseating granulomas with no e/o malignancies on histopathology. The patient was started on anti-tubercular therapy. Six months after the treatment, the lesion had reduced in size and her vision had improved. CONCLUSION: Isolated choroidal tuberculomas can be present in eyes with little associated ocular inflammation and no other symptoms of systemic tuberculosis. High suspicion, early diagnosis and rapid initiation of medication are important for the treatment of ocular and systemic tuberculosis.


Choroid Diseases , Tuberculoma , Tuberculosis, Ocular , Humans , Female , Child , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Tuberculoma/diagnostic imaging , Tuberculoma/drug therapy , Granuloma/diagnosis , Granuloma/drug therapy , Granuloma/etiology , Choroid , Choroid Diseases/diagnosis , Choroid Diseases/drug therapy , Choroid Diseases/etiology
6.
Retin Cases Brief Rep ; 17(4): 430-432, 2023 Jul 01.
Article En | MEDLINE | ID: mdl-37364203

PURPOSE: To report a challenging case of tuberculous chorioretinitis. METHODS: Case report of a 51-year-old woman from the Middle East, who was referred from an optometrist with a suspicious retinal lesion in her right eye. RESULTS: Clinical examination showed multifocal, pale, elevated lesions temporal to the right macula with no vasculitis or hemorrhages. Infective and inflammatory workup showed unremarkable results. B-scan ultrasound confirmed an 8 mm × 3 mm × 10 mm right focal chorioretinal thickening. Computed tomography scanning showed calcified lung hilar nodes supporting a prior granulomatous process, along with an enhancing nodule in the right globe. Magnetic resonance imaging of the brain and obits showed retinal thickening of the temporal surface of the right globe with subtle enhancement without retrobulbar extension or evidence for cerebral vasculitis. Subretinal lesion biopsy showed mononuclear inflammatory cells with granulomatous inflammation, including multinucleated giant cells but no neoplastic features. Interferon-gamma release assay testing for tuberculosis showed negative result, but a high index of suspicion lead to tuberculin skin testing and subsequent treatment for tuberculous chorioretinitis. CONCLUSION: Ocular tuberculosis presents in a variety of ways, making it a challenging diagnosis. Herein, we describe such case of tuberculous chorioretinitis.


Chorioretinitis , Eye Diseases , Tuberculosis, Ocular , Female , Humans , Middle Aged , Tuberculosis, Ocular/drug therapy , Chorioretinitis/drug therapy , Biopsy , Tuberculin Test/adverse effects
7.
Prog Retin Eye Res ; 95: 101189, 2023 Jul.
Article En | MEDLINE | ID: mdl-37236420

Tubercular uveitis (TB-uveitis) remains a conundrum in the uveitis field, which is mainly related to the diverse clinical phenotypes of TB-uveitis. Moreover, it remains difficult to differentiate whether Mycobacterium tuberculosis (Mtb) is present in the ocular tissues, elicits a heightened immune response without Mtb invasion in ocular tissues, or even induces an anti-retinal autoimmune response. Gaps in the immuno-pathological knowledge of TB-uveitis likely delay timely diagnosis and appropriate management. In the last decade, the immunopathophysiology of TB-uveitis and its clinical management, including experts' consensus to treat or not to treat certain conditions with anti-tubercular treatment (ATT), have been extensively investigated. In the meantime, research on TB treatment, in general, is shifting more toward host-directed therapies (HDT). Given the complexities of the host-Mtb interaction, enhancement of the host immune response is expected to boost the effectiveness of ATT and help overcome the rising burden of drug-resistant Mtb strains in the population. This review will summarize the current knowledge on the immunopathophysiology of TB-uveitis and recent advances in treatment modalities and outcomes of TB-uveitis, capturing results gathered from high- and low-burden TB countries with ATT as the mainstay of treatment. Moreover, we outline the recent progress of HDT development in the pulmonary TB field and discuss the possibility of its applicability to TB-uveitis. The concept of HDT might help direct future development of efficacious therapy for TB-uveitis, although more in-depth research on the immunoregulation of this disease is still necessary.


Mycobacterium tuberculosis , Tuberculosis, Ocular , Uveitis , Humans , Antitubercular Agents/therapeutic use , Antitubercular Agents/pharmacology , Tuberculosis, Ocular/drug therapy , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/microbiology , Mycobacterium tuberculosis/genetics , Uveitis/drug therapy , Uveitis/diagnosis , Immunity
8.
Acta Med Port ; 36(10): 683-686, 2023 Oct 02.
Article En | MEDLINE | ID: mdl-37080196

A 17-year-old male was taken to the emergency department for decreased left visual acuity and floaters beginning that same day. There was a history of exposure to pulmonary tuberculosis five years before (mother as index case) followed by a four-month period of isoniazid prophylaxis. The ophthalmic examination showed posterior and intermediate uveitis in the left eye. Laboratory tests were normal; IgG for herpes simplex 1 was positive and both the varicella-zoster virus and remaining serologic tests were negative. Chest radiography was normal. Two weeks later, an epiretinal membrane with risk of tractional retinal detachment was observed. The Mantoux tuberculin skin test showed an induration of 15 mm and the IGRA test was positive. Sputum and vitreous humor samples were collected. Quadruple therapy and prednisolone were started. Ten days later, a posterior vitreous detachment with underlying vitreous hematoma was observed. Posterior vitrectomy and peripheral endolaser were performed without complications. One month later, the microbiological results became available, with the identification of Mycobacterium tuberculosis. Corticosteroids were weaned progressively. Antituberculous drugs were maintained for six months. The patient made a full recovery.


Eye Diseases , Mycobacterium tuberculosis , Tuberculosis, Ocular , Male , Humans , Child , Adolescent , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Tuberculosis, Ocular/surgery , Vitreous Body/microbiology , Vitreous Body/surgery , Vitrectomy , Eye Diseases/surgery
9.
J Fr Ophtalmol ; 46(3): 231-234, 2023 Mar.
Article En | MEDLINE | ID: mdl-36725373

An 18-year-old female patient was referred with complaints of tearing and redness in the left eye for 3 months after a mild ocular trauma with a turkey feather. She was treated with topical antibiotics and corticosteroids with no improvement. Slit-lamp examination of the left eye showed a vascularized lesion with a polypoidal appearance due to multiple contiguous micronodules on the temporal and inferior bulbar conjunctiva. Results of the anterior and posterior segment examination were unremarkable in both eyes. A biopsy specimen of the conjunctival mass showed multiple tuberculoid granulomas composed of epithelioid histiocytes with associated Langhan's type multinucleate giant cells and a necrotic nodule surrounded by histiocytes and giant cells. The Mantoux test was positive with induration of 15mm. The patient was prescribed antituberculosis therapy. Three months after treatment initiation, the conjunctival lesions had resolved. Mycobacterium tuberculosis should be considered in cases of unilateral chronic recalcitrant conjunctivitis. Biopsy of a conjunctival mass is of utmost importance to establish a definite diagnosis.


Conjunctival Diseases , Conjunctivitis , Tuberculosis, Ocular , Female , Humans , Adolescent , Tuberculosis, Ocular/complications , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Conjunctivitis/pathology , Granuloma/complications , Granuloma/diagnosis , Granuloma/pathology , Conjunctiva/pathology , Conjunctival Diseases/diagnosis , Conjunctival Diseases/etiology , Conjunctival Diseases/pathology
10.
Surv Ophthalmol ; 68(2): 241-256, 2023.
Article En | MEDLINE | ID: mdl-36272559

We quantitatively evaluated the efficacy of antitubercular therapy (ATT) in tubercular uveitis (TBU) patients. Main outcome measures include inflammation recurrence, inflammation reduction, complete resolution of inflammation, improved visual acuity (VA), ability to taper corticosteroids to < 10 mg/day without inflammatory progression, and use of adjunctive immunosuppressants while on ATT. This review is prospectively registered in PROSPERO (CRD42020206845). Forty-nine studies reporting data for 4,017 TBU patients were included. In comparative studies, the odds ratio (OR) of inflammatory recurrence was 0.33 (95%CI:0.19-0.60) for TBU patients treated with ATT±corticosteroid versus no ATT. For TBU patients treated with ATT±corticosteroid, the pooled absolute incidences of inflammatory recurrence, inflammatory reduction, complete resolution of inflammation, and visual acuity improvement were 13% (n=310/2,216; 95%CI:9-18), 81% (n=217/276; 95%CI: 62-95), 83% (n=1,167/1,812; 95%CI: 77-89), and 65% (n=347/542; 95%CI:51-78), respectively. Corticosteroids were tapered to <10 mg/day without inflammatory progression in 91% (n=326/395; 95%CI:78-99) of patients, 9% (n=121/1,376; 95%CI:6-13) of whom were administered concomitant immunosuppressive agents alongside ATT. We conclude that treatment of TBU with ATT±corticosteroid is associated with a high level of control or improvement of inflammation. More prospective studies with detailed reporting of ATT regimens, patient subgroups, and outcomes are required to better evaluate ATT effectiveness.


Tuberculosis, Ocular , Uveitis , Humans , Prospective Studies , Retrospective Studies , Tuberculosis, Ocular/drug therapy , Tuberculosis, Ocular/complications , Uveitis/drug therapy , Uveitis/complications , Antitubercular Agents/therapeutic use , Inflammation , Adrenal Cortex Hormones/therapeutic use , Immunosuppressive Agents/therapeutic use
11.
Eye (Lond) ; 37(7): 1416-1423, 2023 05.
Article En | MEDLINE | ID: mdl-35764876

OBJECTIVE: To introduce the Collaborative Ocular Tuberculosis Study (COTS) Calculator, an online clinical scoring system for initiating antitubercular therapy (ATT) in patients with ocular tuberculosis (TB). METHOD: The COTS Calculator was derived from COTS Consensus (COTS CON) data, which has previously published consensus guidelines. Using a two-step Delphi method, 81 experts evaluated 486 clinical scenario-based questions, ranking their likelihood of initiating ATT in each specific scenario. Each scenario was a permutation of the results and/or availability of five following components-clinical phenotype, endemicity, two immunological (tuberculin skin test, interferon-γ release assay) and one radiological (chest X-Ray) test results-and a sixth component further stratifying three of the clinical phenotypes. The median scores and interquartile ranges (IQR) of each scenario were tabulated, representing the expert consensus on whether to initiate ATT in that scenario. The consensus table was encoded to develop the COTS Calculator. RESULTS: The COTS Calculator can be accessed online at: https://www.oculartb.net/cots-calc . The attending physician can select the conditions present in the patient, which will generate a median score from 1 to 5. 114 out of 486 scenarios (24%) deliberated had a median score of 5 indicating expert consensus to initiate ATT. CONCLUSION: The COTS Calculator is an efficient, low-cost, evidence and experience-based clinical tool to guide ATT initiation. While it holds substantial promise in improving standard-of-care for ocular-TB patients, future validation studies can help to as certain its clinical utility and reliability.


Tuberculosis, Ocular , Humans , Reproducibility of Results , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Antitubercular Agents/therapeutic use , Cognition , Consensus
12.
Br J Ophthalmol ; 107(4): 495-499, 2023 04.
Article En | MEDLINE | ID: mdl-34799367

AIMS: To evaluate the clinical characteristics and therapeutic outcome of patients with recurrent scleritis of unknown demonstrable aetiology and positive QuantiFERON-TB Gold In-Tube test (QFT). METHODS: Retrospective chart review of the demographic, clinical, laboratory and therapeutic outcome data of 15 patients. Clinical characteristics as well as remission rate after standard antituberculous therapy (ATT) were assessed. RESULTS: There were 9 men and 6 women with a mean age of 48.9 years (range, 32-73). Scleritis was diffuse in 10 patients (66.6%) and nodular in 5 patients (33.3%), 1 of them with concomitant posterior scleritis. It was bilateral in 7 patients (46.6%) and recurrent in all of them. Scleritis appeared after prior uveitis (10 patients, 66.6%) and/or with concomitant uveitis (5 patients, 33.3%) or peripheral keratitis (5 patients, 33.3%). Previous ocular surgery was found in 7 patients (46.6%). Previous extraocular tuberculosis (TB) infection or previous TB contact was detected in 11 patients (73.3%). No radiologic findings of active extraocular TB were detected. ATT was used in 15 patients, sometimes with the addition of systemic corticosteroids (5 patients) and methotrexate (1 patient); 14 patients achieved complete remission (93.3%). CONCLUSION: Presumed TB-related scleritis may appear in recurrent scleritis of unknown origin and positive QFT. It may occur after prior uveitis and/or concomitantly with uveitis or peripheral keratitis, and it may be triggered by previous ocular surgery. No patients had evidence of concurrent active extraocular infection, although many had previous TB infection or TB contact. ATT was effective, sometimes with the addition of systemic corticosteroids and methotrexate.


Keratitis , Scleritis , Tuberculosis, Ocular , Tuberculosis , Uveitis , Male , Humans , Female , Middle Aged , Scleritis/diagnosis , Scleritis/drug therapy , Scleritis/etiology , Tuberculosis, Ocular/complications , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Tuberculin Test/adverse effects , Antitubercular Agents/therapeutic use , Retrospective Studies , Methotrexate/therapeutic use , Uveitis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Keratitis/drug therapy , Tuberculosis/drug therapy
13.
Ocul Immunol Inflamm ; 31(5): 914-920, 2023 Jul.
Article En | MEDLINE | ID: mdl-35442853

BACKGROUND: Xpert MTB/RIF Ultra (Ultra) was evaluated for the first time on Ocular tuberculosis (OTB) samples and compared with Xpert. METHODS: Seventy five vitreous fluid samples (3 confirmed OTB, 47 clinically suspected OTB, and 25 controls) were subjected to Ultra, Xpert and Multiplex-PCR and compared against culture, composite reference standard (CRS), and gene sequencing. RESULTS: The sensitivity of Ultra was 50% in diagnosing OTB (100% against culture and 46.8% against CRS). The overall sensitivity of Xpert and MPCR was 16% and 72%, respectively. Xpert missed three culture-positive cases and MPCR detected additional 11. Ultra and Xpert missed two and four cases of RifR, respectively. A total of 13(59%) cases were reported 'trace' by Ultra in which RifR could not be evaluated. CONCLUSION: Ultra outperformed Xpert in diagnosing OTB. The advantage of Ultra's simultaneous RifR detection is lost since the trace bacterial loads in the specimens cause indeterminate results of RifR testing.Abbreviations: OTB: Ocular tuberculosis; Ultra: Xpert MTB/RIF Ultra; Xpert: Xpert MTB/RIF, MPCR: multiplex polymerase chain reaction; NAATs: Nucleic acid amplification tests; MLAMP: multitargeted loop-mediated isothermal amplification; PPV: positive predictive value; NPV: negative predictive value; EPTB: extrapulmonary tuberculosis; VF: vitreous fluid; DNA: deoxyribonucleic acid; ATT: antitubercular therapy; RifR: Rifampicin resistance; RifS: Rifampicin susceptible; RifI: Rifampicin indeterminate.


Antibiotics, Antitubercular , Mycobacterium tuberculosis , Tuberculosis, Ocular , Tuberculosis , Humans , Antibiotics, Antitubercular/pharmacology , Antibiotics, Antitubercular/therapeutic use , Drug Resistance, Bacterial/genetics , Mycobacterium tuberculosis/genetics , Rifampin/pharmacology , Rifampin/therapeutic use , Sensitivity and Specificity , Tuberculosis/diagnosis , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Vitrectomy
14.
Ocul Immunol Inflamm ; 31(1): 158-167, 2023 Jan.
Article En | MEDLINE | ID: mdl-34919497

PURPOSE: To report pre and post treatment levels of VEGF-A in the aqueous humour of patients with intraocular tubercular granulomas and study the effect of a combined intravitreal anti-VEGF bevacizumab and moxifloxacin therapy on their regression. METHODS: Aqueous samples of 10 consecutive patients with intraocular tubercular granulomas obtained before and after initiating treatment were subjected to ELISA for analysing intraocular VEGF-A levels. Intravitreal injections of bevacizumab and moxifloxacin were given weekly till complete regression of these granulomas. All patients received the usual four-drug ATT and oral corticosteroids. RESULTS: Mean baseline VEGF-A level was 1004.27±411.40 pg/ml (401.32-1688.95) that reduced significantly to 27.62±46.86 pg/ml (6.9-131.83) at the last injection. Meannumber of intravitreal injections was 3.1 (2-4). We found significant correlation of decreasing levels of aqueous VEGF-A with the clinical regression of these tubercular granulomas. CONCLUSIONS: Intraocular TB granulomas have high levels of VEGF-A. Weekly intravitreal injections of anti-VEGF bevacizumab with moxifloxacin as an adjunct to the standard care may cause prompt regression of tubercular granulomas. ABBREVIATIONS: TB: Tuberculosis; IOTB: Intraocular tuberculosis; VEGF: Vascular endothelial growth factor; RD: Retinal detachment; Mtb: Mycobacterium tuberculosis; ATT: Antitubercular therapy; AMD: Age-related macular degeneration; SRF: Subretinal fluid; ELISA: Enzyme immunosorbent assay; PCR: Polymerase chain reaction; ONH: Optic nerve head; MDR-TB: Multidrug-resistant tuberculosis; pg/ml: picogram/milliliter; ESR: Erythrocyte sedimentation rate; CECT: Contrast enhanced computed tomography; DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid; BSL: Biosafety level; BCVA: Best corrected visual acuity; HM: Hand movements; KP: Keratic precipitates; PSC: Posterior subcapsular cataract; PS: Posterior synechiae; CRA: Chorio-retinal atrophy; IVMP: Intravenous methyl prednisolone; OCT: Optical coherence tomography; RPE: Retinal pigment epithelium; FFA: Fundus fluorescein angiography; ICG: Indocyanine angiography; RAP: Retinal arterial proliferans.


Angiogenesis Inhibitors , Granuloma , Tuberculosis, Ocular , Vascular Endothelial Growth Factor A , Humans , Bevacizumab/therapeutic use , Fluorescein Angiography , Granuloma/drug therapy , Intravitreal Injections , Moxifloxacin , Ranibizumab , Tomography, Optical Coherence , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Tuberculosis, Ocular/drug therapy
15.
Br J Ophthalmol ; 107(4): 500-504, 2023 04.
Article En | MEDLINE | ID: mdl-34711577

AIMS: Few studies have evaluated the contribution of QuantiFERON test for the diagnosis of tubercular uveitis in non-endemic countries for tuberculosis (TB). The objective of the present study was to evaluate the value of the QuantiFERON test in a large cohort of patients with uveitis for both the diagnosis of tubercular uveitis and antituberculosis treatment (ATT) response prediction. METHODS: A single-centre retrospective study including consecutive adult patients with uveitis who were prescribed a QuantiFERON test between January 2003 and December 2019 was performed. Adjusted ORs (aORs) were calculated between patients with uveitis responding and not responding to ATT according to the Collaborative Ocular Tuberculosis Study (COTS) group diagnostic criteria. Sensitivity (SE), specificity (Sp), and positive and negative predictive values of the QuantiFERON test were calculated. RESULTS: A total of 1075 patients were included in the study; 178 (16.5%) were found positive using the QuantiFERON test. Among the 178 positive patients, 62 (35%) had a diagnosis of tubercular uveitis according to the updated COTS classification; all received ATT for 6 months; and 44/62 (71%) responded to ATT. A QuantiFERON test value of >2 IU/mL was associated with a greater chance of responding to ATT (aOR=36.7, 95% CI 7.2 to 185.9, p<0.001). The optimal threshold to maximise both Sp and SE for diagnosis of TB uveitis was 4 IU/mL. CONCLUSION: One-sixth of the patients diagnosed with uveitis had a positive QuantiFERON test. The QuantiFERON threshold with the optimal SE and Sp for the diagnosis of tubercular uveitis was 4 IU/mL. TRIAL REGISTRATION NUMBER: NCT03863782.


Tuberculosis, Ocular , Uveitis , Adult , Humans , Antitubercular Agents/therapeutic use , Retrospective Studies , Tuberculin Test , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Uveitis/diagnosis , Uveitis/drug therapy
16.
Ocul Immunol Inflamm ; 31(2): 304-311, 2023 Feb.
Article En | MEDLINE | ID: mdl-35081020

PURPOSE: To assess the performance of interferon-gamma release assay (IGRA) associated with tuberculosis skin test (TST) for ocular tuberculosis (OTB) diagnosis and therapeutic decision making. METHOD: One hundred and ninety-one patients with ocular inflammation were prospectively followed-up. Patients with clinical signs highly suspected of OTB, TST≥10 mm, and/or IGRA≥0.35 IU/mL received antitubercular therapy (ATT). Sensitivity (Se), specificity (Sp), and area under the curve (AUC) were assessed. RESULTS: Seventy-two (37.7%) patients received ATT for presumed OTB. Combining TST and IGRA had Se=89.6%, Sp=99.2%, and AUC (0.98) significantly higher compared to TST (0.85, Z=6.3, p<.001) or IGRA (0.95, Z=2.5, p=.01). Prior history of corticosteroids or immunosuppressant with concomitantly oral prednisone and baseline IGRA> 2.0 IU/mL was associated significantly with more recurrences in ATT patients (p=.01)      . CONCLUSION: Considering TST and IGRA together was more effective in assessing OTB diagnosis. The real value of the IGRA test to predict recurrences needs further studies.


Latent Tuberculosis , Tuberculosis, Ocular , Tuberculosis , Humans , Interferon-gamma Release Tests , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Tuberculosis, Ocular/complications , Follow-Up Studies , Tuberculin Test , Tuberculosis/complications , Antitubercular Agents/therapeutic use , Recurrence , Latent Tuberculosis/diagnosis
17.
Eur J Ophthalmol ; 33(1): NP15-NP18, 2023 Jan.
Article En | MEDLINE | ID: mdl-34420419

The diagnosis of OTB (Ocular tuberculosis) is usually difficult to make. Definitive diagnosis requires the identification of M. tuberculosis organisms in ocular tissues or fluids, but samples are often difficult to obtain, and biopsy may be hard to justify. We describe a 50-years-old Maghreb male, who presented a multifocal choroiditis associated with a choroidal tuberculoma on the left eye. Based on positive QuantiFERON-TB-Gold test and suggestive clinical and radiographic findings, a diagnosis of presumed ocular tuberculosis was made. Serial swept-source optical coherence tomography (SS-OCT) and widefield fundus retinographies during subsequent follow-up visits demonstrated the characterization of the atypical tuberculosis presentation and allowed the assessment of response to antitubercular therapy and oral steroids.


Choroiditis , Tuberculoma , Tuberculosis, Ocular , Humans , Male , Middle Aged , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Tuberculosis, Ocular/complications , Multifocal Choroiditis/complications , Multifocal Choroiditis/drug therapy , Multifocal Choroiditis/pathology , Choroid/pathology , Diagnostic Techniques, Ophthalmological , Antitubercular Agents/therapeutic use , Tuberculoma/diagnosis , Tuberculoma/drug therapy , Tuberculoma/complications , Choroiditis/diagnosis , Choroiditis/drug therapy , Choroiditis/complications , Tomography, Optical Coherence/methods , Fluorescein Angiography/methods
18.
J Med Life ; 15(8): 1058-1062, 2022 Aug.
Article En | MEDLINE | ID: mdl-36188648

Tuberculosis of the eye represents a challenge throughout the world, and there is a continuous debate about its pathophysiology, diagnosis, and treatment. The present research represents an interventional prospective study focusing on the variable clinical presentations, and the diagnostic and therapeutic characteristics of ocular tuberculosis. Fifteen eyes from nine cases were diagnosed with ocular tuberculosis, treated, and followed up between 2010 and 2020. The diagnosis was based on (1) a compatible clinical picture, (2) highly positive Tuberculin skin test or a positive IGRA test (Interferon-Gamma Release Assays), (3) a dramatic response to anti-tuberculous drugs without systemic steroid. Mean age was 41.22±13.64 years; eight cases were females 89.8%, one male 11.1%. Only one case had preexisting pulmonary tuberculosis. Bilateral ocular involvement occurred in two thirds of cases (66.7%). The most common clinical presentation was intermediate uveitis (33.3%), followed by multifocal choroiditis (20%). All cases were cured without relapse for the 2-10 years of follow-up, after taking oral anti-tuberculous drugs for 6-12 months. No systemic steroids were given, only topical steroid drops, as indicated. In conclusion, ocular tuberculosis is a mysterious condition with a wide-range of clinical presentations and should be considered in the differential diagnoses of any type of intraocular inflammation, or any unexplained reduction in vision. Oral anti-tuberculous drugs with or without topical steroids are sufficient to improve vision, produce, cure, and prevent relapse.


Tuberculosis, Ocular , Tuberculosis , Adult , Female , Humans , Male , Middle Aged , Prospective Studies , Recurrence , Tuberculin Test , Tuberculosis/diagnosis , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy
19.
BMJ Open Respir Res ; 9(1)2022 03.
Article En | MEDLINE | ID: mdl-35379660

The BTS clinical statement for the diagnosis and management of ocular tuberculosis (TB) draws on the expertise of both TB and and ophthalmic specialists to outline the current understanding of disease pathogenesis, diagnosis and management in adults. Published literature lacks high-quality evidence to inform clinical practice and there is also a paucity of data from animal models to elucidate mechanisms of disease. However, in order to improve and standardise patient care, this statement provides consensus points with the currently available data and agreed best practice.


Tuberculosis, Ocular , Animals , Consensus , Humans , Models, Animal , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy
...